Table of Contents
Overview
New York, NY – June 19, 2025 – Global Ablation Devices Market size is expected to be worth around US$ 14.5 Billion by 2034 from US$ 7.1 Billion in 2024, growing at a CAGR of 7.4% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 39.2% share with a revenue of US$ 2.8 Billion.
Ablation devices are minimally invasive medical instruments designed to remove or destroy diseased tissue using energy sources such as radiofrequency, microwave, laser, or cryotherapy. These devices are widely utilized in treating cardiac arrhythmias, cancerous tumors, chronic pain, and varicose veins. The adoption of ablation technologies is growing due to their ability to deliver precise, localized treatment while minimizing damage to surrounding healthy tissues.
The clinical use of ablation has gained momentum in both inpatient and outpatient settings, supported by favorable safety profiles and reduced recovery times. In cardiology, catheter-based radiofrequency ablation is considered a frontline treatment for atrial fibrillation, a condition that affects over 33 million people globally. In oncology, thermal ablation techniques such as microwave and radiofrequency ablation are increasingly used to treat liver, kidney, and lung tumors, especially in patients who are not eligible for surgery.
Ablation procedures are typically guided by advanced imaging systems, ensuring accurate targeting and effective outcomes. Government health agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have approved a broad range of ablation systems for various therapeutic indications. As healthcare systems prioritize less invasive treatment options with shorter hospital stays, ablation devices are expected to play a critical role in the evolving landscape of modern medicine.
Key Takeaways
- In 2023, the ablation devices market recorded a revenue of US$ 7.1 billion and is projected to reach US$ 14.5 billion by 2033, registering a CAGR of 7.4%.
- By product type, radiofrequency devices held the leading position with a 54.3% market share in 2023, followed by ultrasound, laser/light, cryoablation, and other devices.
- Based on application, cardiology accounted for the largest share at 49.2%, with other segments including oncology, gynecology, ophthalmology, and others.
- In terms of end users, hospitals dominated the market with a 56.8% revenue share, ahead of ambulatory surgery centers and other healthcare settings.
- Regionally, North America emerged as the leading market, contributing 39.2% of the global revenue in 2023.
Segmentation Analysis
- Product Type Analysis: In 2023, radiofrequency devices dominated the product type segment with a 54.3% market share, driven by rising demand for minimally invasive procedures. This method is commonly used to treat cardiac arrhythmias, tumors, and varicose veins due to its precision and reduced collateral tissue damage. The growing prevalence of chronic diseases such as cancer and cardiovascular disorders, coupled with advancements in electrode designs and energy systems, is expected to support sustained growth in this segment.
- Application Analysis: Cardiology accounted for 49.2% of the ablation devices market in 2023, primarily due to the increasing incidence of cardiovascular diseases like arrhythmias. Radiofrequency ablation has become a standard treatment, especially for atrial fibrillation, among the aging global population. The shift toward less invasive cardiac procedures and continual innovation in ablation technology to enhance safety and accuracy are anticipated to further expand the cardiology segment’s role within the broader market landscape.
- End-User Analysis: Hospitals held a leading 56.8% share of the end-user segment in 2023, serving as central hubs for advanced ablation procedures. Their access to skilled professionals and modern infrastructure enables the treatment of complex conditions such as cancer, arrhythmias, and chronic pain. As healthcare systems prioritize minimally invasive care and expand investments in medical technologies, hospitals are expected to remain dominant, with increasing adoption of innovative ablation systems to improve procedural outcomes and patient recovery.
Market Segments
By Product Type
- Radiofrequency devices
- Ultrasound devices
- Laser/light ablation
- Cryoablation devices
- Others
By Application
- Cardiology
- Oncology
- Gynecology
- Ophthalmology
- Others
By End-user
- Hospitals
- Ambulatory surgery centers
- Others
Regional Analysis
North America led the ablation devices market in 2023, accounting for 39.2% of global revenue. This dominance is attributed to the high prevalence of chronic diseases, rapid technological innovation, and increased insurance coverage. The American Cancer Society recorded 2 million new cancer diagnoses in the U.S. in 2023, many of which required tumor ablation.
Additionally, the Centers for Medicare & Medicaid Services approved 23% more ablation procedure reimbursements than in 2022, enhancing accessibility. The FDA cleared 15 new ablation technologies in 2023, supporting advancements in cardiac and neurological care. According to the American Heart Association, cardiac ablation procedures rose by 18% year-over-year due to increased atrial fibrillation cases. Leading hospitals like Mayo Clinic and Cleveland Clinic reported a 30% increase in minimally invasive ablation surgeries.
Asia Pacific is projected to witness the fastest CAGR during the forecast period. China recorded a 25% increase in cancer ablation procedures, while Japan approved 12 new devices in 2023. India’s Ayushman Bharat allocated US$150 million for surgical technologies, including ablation systems. With a 40% rise in thyroid ablation cases in South Korea and growing demand for cardiac ablations, the region shows robust growth potential.
Market Dynamics
Driver
The demand for ablation devices can be attributed to the rising prevalence of atrial fibrillation. It is estimated that 12.1 million Americans will have AFib by 2030, with over 454 000 hospitalizations and 232 030 death certificates mentioning AFib in 2021. Early intervention through catheter ablation is increasingly recommended over drug therapy for select cases, driving device adoption.
Trend
Regulatory approvals for pulsed field ablation (PFA) systems have accelerated market innovation. The FARAPULSE™ PFA system received FDA premarket approval on January 30, 2024, following Medtronic’s PulseSelect™ PFA system approval on December 13, 2023. These clearances reflect a shift toward irreversible electroporation technologies, enabling faster treatment protocols and expanded clinical use, and are expected to set a precedent for next-generation ablation solutions.
Restraint
Market adoption is constrained by reimbursement uncertainty and coding complexity. A new HCPCS code (C8005) for transbronchial pulsed electric field lung tumor ablation became effective April 1, 2025, yet coverage policies under the Outpatient Prospective Payment System remain under development. Additionally, CPT codes for intracardiac catheter ablation integrate essential monitoring services—such as TEE—into a single code, preventing separate billing for imaging, which can deter provider uptake.
Opportunity
The expanding use of ablation in oncology presents significant opportunity. According to IARC, 905 700 people were diagnosed with liver cancer worldwide and 830 200 died in 2020; projections estimate 1.4 million cases by 2040. Minimally invasive ablation procedures—such as radiofrequency, microwave, and PEF offer effective local tumour control in hepatocellular carcinoma, positioning ablation devices to address a growing global cancer burden.
Conclusion
The ablation devices market is poised for sustained growth, driven by rising demand for minimally invasive treatments across cardiology, oncology, and chronic care applications. Strong clinical adoption, especially in hospitals, is supported by improved outcomes, shorter recovery times, and expanding reimbursement coverage. Technological advancements such as pulsed field ablation and favorable regulatory approvals are accelerating innovation.
While reimbursement complexities present challenges, increasing cancer prevalence and the global shift toward precision therapies offer significant opportunities. With North America leading in adoption and Asia Pacific emerging as a high-growth region, ablation devices are expected to remain a critical component of modern therapeutic strategies.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
